>AT2G26910.1 | PDR4 (PLEIOTROPIC DRUG RESISTANCE 4) ATPase coupled to transmembrane movement of substances
MWNSAENAFSRSTSFKDEIEDEEELRWAALQRLPTYSRIRRGIFRDMVGEPKEIQIGNLE
ASEQRLLLDRLVNSVENDPEQFFARVRKRFDAVDLKFPKIEVRFQNLMVESFVHVGSRAL
PTIPNFIINMAEGLLRNIHVIGGKRNKLTILDGISGVIRPSRLTLLLGPPSSGKTTLLLA
LAGRLGTNLQTSGKITYNGYDLKEIIAPRTSAYVSQQDWHVAEMTVRQTLEFAGRCQGVG
FKYDMLLELARREKLAGIVPDEDLDIFMKSLALGGMETSLVVEYVMKILGLDTCADTLVG
DEMIKGISGGQKKRLTTGELLVGPARVLFMDEISNGLDSSTTHQIIMYMRHSTHALEGTT
VISLLQPSPETYELFDDVILMSEGQIIYQGPRDEVLDFFSSLGFTCPDRKNVADFLQEVT
SKKDQQQYWSVPFRPYRYVPPGKFAEAFRSYPTGKKLAKKLEVPFDKRFNHSAALSTSQY
GVKKSELLKINFAWQKQLMKQNAFIYVFKFVQLLLVALITMTVFCRTTMHHNTIDDGNIY
LGSLYFSMVIILFNGFTEVPMLVAKLPVLYKHRDLHFYPSWAYTLPSWLLSIPTSIIESA
TWVAVTYYTIGYDPLFSRFLQQFLLYFSLHQMSLGLFRVMGSLGRHMIVANTFGSFAMLV
VMTLGGFIISRDSIPSWWIWGYWISPLMYAQNAASVNEFLGHNWQKTAGNHTSDSLGLAL
LKERSLFSGNYWYWIGVAALLGYTVLFNILFTLFLAHLNPWGKFQAVVSREELDEREKKR
KGDEFVVELREYLQHSGSIHGKYFKNRGMVLPFQPLSLSFSNINYYVDVPLGLKEQGILE
DRLQLLVNITGAFRPGVLTALVGVSGAGKTTLMDVLAGRKTGGTIEGDVYISGFPKRQET
FARISGYCEQNDVHSPCLTVVESLLFSACLRLPADIDSETQRAFVHEVMELVELTSLSGA
LVGLPGVDGLSTEQRKRLTIAVELVANPSIVFMDEPTSGLDARAAAIVMRTVRNIVNTGR
TIVCTIHQPSIDIFESFDELLFMKRGGELIYAGPLGQKSCELIKYFESIEGVQKIKPGHN
PAAWMLDVTASTEEHRLGVDFAEIYRNSNLCQRNKELIEVLSKPSNIAKEIEFPTRYSQS
LYSQFVACLWKQNLSYWRNPQYTAVRFFYTVVISLMLGTICWKFGSKRDTQQQLFNAMGS
MYAAVLFIGITNATAAQPVVSIERFVSYRERAAGMYSALPFAFAQVFIEFPYVLAQSTIY
STIFYAMAAFEWSAVKFLWYLFFMYFSIMYFTFYGMMTTAITPNHNVASIIAAPFYMLWN
LFSGFMIPYKRIPLWWRWYYWANPVAWTLYGLLVSQYGDDERSVKLSDGIHQVMVKQLLE
DVMGYKHDFLGVSAIMVVAFCVFFSLVFAFAIKAFNFQRR*
>AT3G30842.1 | PDR10 (PLEIOTROPIC DRUG RESISTANCE 10) ATP binding / ATPase/ nucleoside-triphosphatase/ nucleotide binding
MAHYRVSSEVENIMNRDRSHRKNEEEDEEEALKLAAMEKLQRLPTYDRARKAVLKGITGG
FKEIDMKDLGLAERRELFDRVMTMDDEDWHGEYLRRLKSRFDRVSLHLPTIEVRFEDLNV
TAEAYAGSKTVPTVLNSYVNLLKGIGTKIRVLPDRKKRISILNDVSGIIKPGRLTLLLGP
PGSGKSTLLKALSGKTETGLRSTGKVTYNGHELHEFVPERTAGYIDQYDVHLPDLTVRET
LKFSAKCQGVGTGYDMLAELLRREKDLNIKPDPYLDALMKASVIKGHKEYVVTDYVLKVL
GLEICADTIVGNHMKRGISGGQKKRVTTGEMLVGPVGAFFMDNISDGLDSSTTFQIVKSI
KQMIHVFDKTALISLLQPPPETFELFDDVIILGEGHIVYQGPREDVLEFFEFMGFKCPER
KGIADYLQEILSKKDQEQYWANPELPYRYVTAKKFEEGFKIHHFGRAMRSQLATPFDRLK
NHRAALTRTTYGASKLELLKACLERESILMKRNLRTFVLKSLQLIINAILIGVVFWQQKN
YPSTVEDGIIYMGAIYLEVQMIVFSGFFELPMTIDKLPVFYKQRHFSFYPSWAFSLPTSI
ITFPLSFVEVFIVVLITYFTIGYDLTVPSFLKHYLVLALCGQMSYGLFRCIAAVTRNHVV
SNTMGCLAVMWLMTFSGYVLSRNQVHKWLTWAYWTSPMMYIQTAVSVNEFRSESWKDVIS
KKPFFKFSTSHFKDIKLNRVVYDFQGLGVAVLKSREYGISKTAVLPDEREEADSNNTTGR
DYTGTTMERFFDRVVTTRTCNDKKLRIPFKPLYMTFENITYSVDTPKEMKEKGIRENKLV
LLNGLSGAFRPGVLTALMGVSGAGKTTLMDVLAGRKNTGYIQGEIYVSGFPKKQDSFARV
SGYCEQSDIHSPLLTVYESLLYSAWLRLPPDIDTHTREVMELIELKALREMLVGYVGISG
LSTEQRKRMTIAVELVANPSILFMDEPTSGLDARAAAIVMRTVRNTVDTGRTVVCTIHQP
SIDIFESFDELFLLTRGGEEIYVGPIGHHSSQLIEYFEGIRGVGKIKEGYNPATWALEVT
TRAQEDVLGVTFAQVYKKSNLYRRNKDLIKELNNIPPHAQDIHFSTKYSQSYLSQFQACL
WKQHKSYWRNVPYNAVRFSFGAAVGIMYGIIFWSLGKRKGTRQDIFNSVGAMSTVVGFLS
SQSAATVRPVVIAERTVFYREAGAGMYSALPYAFSQVIIEIPYTMAQACIYGVIVYGMIG
YEWTASKFFLNIFFTFISILYSIYTGIMVISVSPNQEIASILNGVISTSWNVFSGFTIPR
PRMHVWLRWFTYVCPGWWGLYGLTIAQYGDVETRLDTGETVVEFMKNYYGYEYNFLWVVS
LTLIAFSMFFVFIYAFSVKILNFQKR*